Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Profit After Tax: 2011-2025

Historic Profit After Tax for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $36.4 million.

  • Adma Biologics' Profit After Tax rose 1.45% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 207.41%. This contributed to the annual value of $197.7 million for FY2024, which is 800.00% up from last year.
  • Latest data reveals that Adma Biologics reported Profit After Tax of $36.4 million as of Q3 2025, which was up 6.46% from $34.2 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Profit After Tax ranged from a high of $111.9 million in Q4 2024 and a low of -$25.0 million during Q1 2022.
  • Its 3-year average for Profit After Tax is $24.3 million, with a median of $26.9 million in 2025.
  • As far as peak fluctuations go, Adma Biologics' Profit After Tax crashed by 44.26% in 2023, and later spiked by 1,299.96% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' Profit After Tax stood at -$16.6 million in 2021, then increased by 26.54% to -$12.2 million in 2022, then crashed by 44.26% to -$17.6 million in 2023, then soared by 734.15% to $111.9 million in 2024, then increased by 1.45% to $36.4 million in 2025.
  • Its Profit After Tax was $36.4 million in Q3 2025, compared to $34.2 million in Q2 2025 and $26.9 million in Q1 2025.